Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6
Benzinga Newsdesk 44 minutes ago
Analyst RatingsNewsUpgradesPrice Target
Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.
Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.